Because of this, there are concerted efforts to improve the antitumor activity of DR4/DR5 targeted therapies by rationally designing combinational drugs that would overcome or bypass the resistance mechanisms within the cancer cells. The gene discussed is TNFRSF10A; the disease is cancer.